BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38637101)

  • 1. Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models.
    Rypens C; Van Berckelaer C; Berditchevski F; van Dam P; Van Laere S
    Int Rev Cell Mol Biol; 2024; 384():77-112. PubMed ID: 38637101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
    Van Laere SJ; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; van Dam P; Woodward WA; Viens P; Cristofanilli M; Birnbaum D; Dirix L; Reuben JM; Bertucci F
    Clin Cancer Res; 2013 Sep; 19(17):4685-96. PubMed ID: 23396049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of inflammatory breast cancer: a review.
    Bertucci F; Finetti P; Vermeulen P; Van Dam P; Dirix L; Birnbaum D; Viens P; Van Laere S
    Breast; 2014 Oct; 23(5):538-45. PubMed ID: 24998451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
    Funakoshi Y; Wang Y; Semba T; Masuda H; Hout D; Ueno NT; Wang X
    PLoS One; 2019; 14(9):e0222336. PubMed ID: 31532791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and expression analysis of microdissected inflammatory breast cancer.
    Woodward WA; Krishnamurthy S; Yamauchi H; El-Zein R; Ogura D; Kitadai E; Niwa S; Cristofanilli M; Vermeulen P; Dirix L; Viens P; van Laere S; Bertucci F; Reuben JM; Ueno NT
    Breast Cancer Res Treat; 2013 Apr; 138(3):761-72. PubMed ID: 23568481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
    Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
    Bertucci F; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; Van Dam P; Woodward WA; Cristofanilli M; Reuben JM; Dirix L; Viens P; Symmans WF; Birnbaum D; Van Laere SJ
    Ann Oncol; 2014 Feb; 25(2):358-65. PubMed ID: 24299959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
    Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
    Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.
    Remo A; Simeone I; Pancione M; Parcesepe P; Finetti P; Cerulo L; Bensmail H; Birnbaum D; Van Laere SJ; Colantuoni V; Bonetti F; Bertucci F; Manfrin E; Ceccarelli M
    J Transl Med; 2015 May; 13():138. PubMed ID: 25928084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.
    Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Cervera N; Tarpin C; Nguyen C; Xerri L; Houlgatte R; Jacquemier J; Viens P; Birnbaum D
    Cancer Res; 2005 Mar; 65(6):2170-8. PubMed ID: 15781628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.
    Bekhouche I; Finetti P; Adelaïde J; Ferrari A; Tarpin C; Charafe-Jauffret E; Charpin C; Houvenaeghel G; Jacquemier J; Bidaut G; Birnbaum D; Viens P; Chaffanet M; Bertucci F
    PLoS One; 2011 Feb; 6(2):e16950. PubMed ID: 21339811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory breast cancer (IBC): clues for targeted therapies.
    Fernandez SV; Robertson FM; Pei J; Aburto-Chumpitaz L; Mu Z; Chu K; Alpaugh RK; Huang Y; Cao Y; Ye Z; Cai KQ; Boley KM; Klein-Szanto AJ; Devarajan K; Addya S; Cristofanilli M
    Breast Cancer Res Treat; 2013 Jul; 140(1):23-33. PubMed ID: 23784380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
    Provance OK; Lewis-Wambi J
    Breast Cancer Res; 2019 May; 21(1):59. PubMed ID: 31060575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copy Number Variation in Inflammatory Breast Cancer.
    Hazra A; O'Hara A; Polyak K; Nakhlis F; Harrison BT; Giordano A; Overmoyer B; Lynce F
    Cells; 2023 Apr; 12(7):. PubMed ID: 37048158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
    Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
    Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy.
    Zhang Z; Wu H; Shen C; Zhou F
    Biochem Genet; 2024 Apr; 62(2):1021-1039. PubMed ID: 37517031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
    Rypens C; Bertucci F; Finetti P; Robertson F; Fernandez SV; Ueno N; Woodward WA; Van Golen K; Vermeulen P; Dirix L; Viens P; Birnbaum D; Devi GR; Cristofanilli M; Van Laere S
    NPJ Breast Cancer; 2022 Jan; 8(1):12. PubMed ID: 35042871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.
    Valeta-Magara A; Gadi A; Volta V; Walters B; Arju R; Giashuddin S; Zhong H; Schneider RJ
    Cancer Res; 2019 Jul; 79(13):3360-3371. PubMed ID: 31043378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.